
AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Critical Metals today, you have to believe that Tanbreez and the broader rare earth platform can transition from concept to cash flow despite very small current revenue and very large losses. The new US$1.55 billion US rare earth funding package clearly strengthens the policy backdrop for Western-aligned projects like Tanbreez and sits neatly alongside Critical Metals’ Saudi, EU and US offtake arrangements, but it does not remove the company’s immediate execution and funding questions. The stock’s sharp swings and premium price to book suggest expectations are already elevated, even as management leans on PIPEs, convertibles and potential asset sales to bridge sizeable capital needs. In that context, the restructured European Lithium deal helps on dilution optics, yet financing risk and delivering on timelines remain the dominant short term catalysts and pressure points.
However, investors still need to weigh dilution and funding pressures very carefully. Our valuation report here indicates Critical Metals may be overvalued.Explore 10 other fair value estimates on Critical Metals - why the stock might be worth over 4x more than the current price!
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com